ClinicalTrials.gg
TerminatedNCT03433755Updated Mar 27, 2023Results posted

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

A Phase 3 interventional study of evolocumab and placebo in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Amgen. Terminated at 31 sites in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Why this study was terminated
Prematurely Discontinued Amgen decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
259
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
21st of 36
259 · median 308
Started
2019
the only one that year
Phase 3
22 of 36
none open now
Registered
30th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 21st largest by enrollment, is the only one that started in 2019, is one of 22 in phase 3, and was the 30th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study is being done to learn more about evolocumab in Chinese people with primary hypercholesterolemia or mixed dyslipidemia. This study will see if evolocumab will reduce low density lipoprotein cholesterol (LDL-C) in Chinese people who are also taking a certain type of lipid-lowering medication (statins with or without ezetimibe) and whether it causes any side effects.

Read the detailed description

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled study of evolocumab in Chinese participants with hypercholesterolemia and mixed dyslipidemia. Participants who have signed the informed consent form (ICF) will have fasting lipids measured and all inclusion and exclusion criteria assessed. All eligible participants must be taking a maximum appropriate dose of an approved statin, not requiring up titration. Participants should maintain their current diet and exercise regimen.

Treatment and follow-up period will be 12 weeks with an additional phone call or other participant contact at week 14 for those receiving investigational product every 2 weeks (Q2W). The end of study (EOS) for participants on once monthly (QM) investigational product is at the week 12 visit, which must be at least 30 days post last dose of investigational product.

Evolocumab or placebo will be administered by self-injection under the skin at the study site or in an appropriate non-clinic setting (e.g., at home) by spring based prefilled auto injector/pen (AI/Pen). Participants must tolerate an injection of placebo with a prefilled auto injector/pen device to be used during the study prior to randomization.

Participants will be randomly added to 1 of 4 groups using a 2:2:1:1 ratio:

evolocumab 140 mg Q2W (86 participants total) evolocumab 420 mg QM (86 participants total) placebo Q2W (44 participants total) placebo QM (43 participants total). The dose frequencies of Q2W and QM will not be blinded but the identity of investigational product evolocumab or placebo will be blinded.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Keywords

  • Evolocumab
  • Repatha
  • Statin
  • Chinese
  • China
  • Hypercholesterolemia
  • Mixed Dyslipidemia
  • High Cholesterol
  • Lowering cholesterol
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 years of age at signing of form
  • On an approved statin, with or without ezetimibe, at optimal stable daily dose(s) for at least 4 weeks before LDL-C screening and, in the opinion of the investigator, not requiring uptitration
  • Fasting LDL-C as determined by central laboratory at screening ≥ 80 mg/dL
  • Subject meets at least 1 of the following criteria for high/very high cardiovascular (CV) risk:

    • history of coronary artery disease
    • history of ischemic stroke
    • diagnosis of peripheral artery disease
    • an estimated (eGFR) as determined by central laboratory at screening of ≥ 30 but \< 60 ml/min/1.73m\^2
    • diagnosis of diabetes mellitus type 2
    • presence of ≥ 3 of the following risk factors: ≥ 45 years of age if male; ≥ 55 years of age if female; hypertension; smoking; family history of premature cardiovascular disease (CVD; 1st degree of relative: male \< 55 yr, female \< 65 yr); high-density lipoprotein (HDL) cholesterol \< 40 mg/dL; obesity ( ≥ 28 kg/m\^2)

OR

Subject does not meet high/very high CV risk criteria but fasting LDL-C as determined by central laboratory at screening ≥ 130 mg/dl

  • Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) by determined by central laboratory at screening
  • Subject tolerates a screening placebo injection.

Exclusion criteria

Exclusion Criteria:

  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization
  • Planned coronary or other revascularization within 20 weeks of screening
  • (NYHA) III or IV heart failure, or last known \< 30
  • Uncontrolled serious cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 3 months prior to randomization
  • Type 1 diabetes, new-onset ( [Hb]A1c ≥ 6.5% or fasting plasma glucose (FPG) ≥ 126 mg/dL at screening without known diagnosis) or poorly controlled ( ≥ 8.5%) type 2 diabetes, as determined by central laboratory at screening
  • Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) > 180 mmHg or diastolic blood pressure (DBP) > 110 mmHg
  • Subject has taken a cholesterylester transfer protein (CETP) inhibitor in the 12 months prior to randomization
  • Subject has taken in the 6 weeks prior to LDL-C screening: red yeast rice, > 200 mg/day niacin, > 1000 mg/day omega-3 fatty acids (eg, dihydroxyacetone docosahexaenoic acid and eicosapentaenoic acid), stanols or prescription lipid-regulating drugs (eg, bile-acid sequestering resins, fibrates and derivatives) or other cholesterol lowering drugs or lipid-lowering dietary supplements or food additives other than statins and ezetimibe
  • Treatment 3 months prior to LDL-C screening with any of the following drugs: systemic cyclosporine, systemic , (intravenous [IV], intramuscular [IM], or by-mouth [PO]) (Note: hormone replacement therapy is permitted), vitamin A derivatives and retinol derivatives for the treatment of dermatologic conditions (eg, Accutane) (Note: vitamin A in a multivitamin preparation is permitted)
  • Uncontrolled hypothyroidism or hyperthyroidism as defined by thyroid stimulating hormone (TSH) \< 1.0 time the lower limit of normal (LLN) or > 1.5 times the (ULN), respectively, at screening
  • Severe renal dysfunction, defined as an \< 30 ml/min/1.73m\^2 at screening as estimated by method
  • Active liver disease or hepatic dysfunction, defined as (AST) or alanine aminotransferase (ALT) > 3 times the ULN as determined by central laboratory analysis at screening
  • Creatinine kinase (CK) > 5 times the ULN at screening
  • (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years prior to randomization
  • Subject has previously received evolocumab or any other therapy to inhibit PCSK9
  • Subject has known sensitivity to any of the active substances or their to be administered during dosing, eg, carboxymethylcellulose
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
  • History or evidence of any other disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Currently receiving treatment in another device or drug study, or less than 30 days before randomization since ending treatment on another investigational device or drug study(s) or planning to receive other investigational procedures while participating in this study
  • Female subject of not willing to use an acceptable method(s) of effective during treatment with investigational product and for an additional 15 weeks after the end of treatment with investigational product. Female subjects of non-childbearing potential who are not required to use contraception during the study and include those who have had a:

    • hysterectomy
    • bilateral salpingectomy
    • bilateral oophorectomy or
    • who are i. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. [A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

ii. Females on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

Acceptable methods of effective birth control include:

  • sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments; the reliability of sexual abstinence must be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject. [Periodic abstinence (eg., calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence for the duration of a study, and withdrawal are not acceptable methods of contraception])
  • bilateral tubal ligation/occlusion
  • vasectomized partner (provided that partner is the sole sexual partner of the female subject of childbearing potential and that the vasectomized partner has received medical assessment of the surgical success)
  • use of hormonal birth control methods (oral, intravaginal (eg. vaginal ring(s), transdermal, injectable, or implantable)
  • intrauterine devices (IUDs)
  • intrauterine hormonal releasing system (IUS)
  • 2 barrier methods (each partner must use 1 barrier method) the male uses a condom and the female must choose either a diaphragm, OR cervical cap, OR contraceptive sponge with spermicide. If spermicide is not commercially available in the country or region, the 2 barrier method without spermicide is acceptable. (A female condom is not an option due to the risk of tearing when both partners use a condom.)

    • Female subject is pregnant or breast feeding (nursing), planning to become pregnant or planning to breastfeed (nurse) during treatment with investigational product and/or within 15 weeks after the end of treatment with investigational product.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
259 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Placebo subcutaneous (SC) Q2W for 12 weeks

    Drug: placebo

  • Placebo comparator
    Placebo QM

    Placebo SC QM for 12 weeks

    Drug: placebo

  • Experimental
    Evolocumab 140 mg Q2W

    Evolocumab 140 mg SC Q2W for 12 weeks

    Drug: evolocumab

  • Experimental
    Evolocumab 420 mg QM

    Evolocumab 420 mg SC QM for 12 weeks

    Drug: evolocumab

Interventions

  • Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.

    Also known as: Repatha; AMG 145

  • Drugplacebo

    Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.

06

What researchers measure

Primary outcomes

  1. Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  2. Co-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in LDL-C: Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  2. Change From Baseline in LDL-C at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Week 12

  3. Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  4. Percent Change From Baseline in Non-HDL-C at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Week 12

  5. Percent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  6. Percent Change From Baseline in ApoB at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline and Week 12

  7. Percent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  8. Percent Change From Baseline in Total Cholesterol at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline and Week 12

  9. Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 12

    Percentage of participants who were below the target LDL-C of 70 mg/dL (1.8 mmol/L) based on the mean LDL-C data collected at weeks 10 and 12.

    Time frame: Weeks 10 and 12

  10. Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12

    Time frame: Week 12

  11. Percentage of Participants With LDL-C Response: Mean of Weeks 10 and 12

    Percentage of participants who had LDL-C response (50% reduction of LDL-C from baseline) based on the mean LDL-C using the data collected at weeks 10 and 12.

    Time frame: Baseline, Weeks 10 and 12

  12. Percentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 12

    LDL-C Response is defined as a 50% reduction of LDL-C from Baseline.

    Time frame: Baseline and Week 12

  13. Percent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  14. Percent Change From Baseline in Lp(a) at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline and Week 12

  15. Percent Change From Baseline in Triglycerides: Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  16. Percent Change From Baseline in Triglycerides at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline and Week 12

  17. Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  18. Percent Change From Baseline in HDL-C at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline and Week 12

  19. Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline, Weeks 10 and 12

  20. Percent Change From Baseline in VLDL-C at Week 12

    Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline and Week 12

07

Results

Posted Aug 20, 2021

Participant flow

Participants were enrolled at 31 research centers in China from 09 May 2019 to 20 January 2020.

Participant flow — Overall Study
MilestonePlacebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QM
Started42417980
Randomized and treated41417980
Completed40417980
Not completed2000
Withdrew: Lost to follow-up1000
Withdrew: Decision by sponsor1000

Outcome measures

PrimaryCo-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · percent change
Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 121.88 ± 3.72-68.86 ± 3.27-0.36 ± 3.78-70.10 ± 3.21
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -70.73 · 95% CI -77.98 to -63.48Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -69.74 · 95% CI -76.51 to -62.97Treatment difference = Evolocumab QM - Placebo QM
PrimaryCo-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Co-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Co-Primary Endpoint: Percent Change From Baseline in LDL-C at Week 122.48 ± 4.18-68.39 ± 3.552.72 ± 4.25-63.09 ± 3.42
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -70.87 · 95% CI -79.47 to -62.27Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -65.81 · 95% CI -73.97 to -57.66Treatment difference = Evolocumab QM - Placebo QM
SecondaryChange From Baseline in LDL-C: Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C: Mean of Weeks 10 and 12
mg/dLPlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Change From Baseline in LDL-C: Mean of Weeks 10 and 12-0.6 ± 5.4-77.1 ± 4.8-5.8 ± 5.8-83.0 ± 5.0
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -76.5 · 95% CI -86.6 to -66.4Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -77.2 · 95% CI -87.7 to -66.7Treatment difference = Evolocumab QM - Placebo QM
SecondaryChange From Baseline in LDL-C at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 12
mg/dLPlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Change From Baseline in LDL-C at Week 12-0.8 ± 5.8-76.7 ± 5.1-2.1 ± 6.1-75.1 ± 5.0
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -75.9 · 95% CI -87.1 to -64.7Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -73.0 · 95% CI -84.1 to -61.8Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C): Mean of Weeks 10 and 122.36 ± 3.52-58.84 ± 3.10-0.06 ± 3.30-62.20 ± 2.81
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -61.20 · 95% CI -68.04 to -54.37Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -62.15 · 95% CI -67.97 to -56.32Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Non-HDL-C at Week 123.86 ± 3.85-57.59 ± 3.301.78 ± 3.70-54.86 ± 2.99
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -61.45 · 95% CI -69.25 to -53.65Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -56.65 · 95% CI -63.66 to -49.63Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Apolipoprotein B (ApoB): Mean of Weeks 10 and 121.80 ± 3.17-54.45 ± 2.790.07 ± 3.00-56.93 ± 2.54
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -56.26 · 95% CI -62.44 to -50.07Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -57.00 · 95% CI -62.35 to -51.65Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in ApoB at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in ApoB at Week 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in ApoB at Week 122.53 ± 3.55-53.16 ± 3.031.20 ± 3.51-50.01 ± 2.77
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -55.69 · 95% CI -62.98 to -48.41Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -51.21 · 95% CI -58.06 to -44.37Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Total Cholesterol: Mean of Weeks 10 and 121.32 ± 2.74-41.42 ± 2.42-0.09 ± 2.68-44.39 ± 2.28
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -42.74 · 95% CI -48.06 to -37.41Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -44.30 · 95% CI -49.02 to -39.58Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Total Cholesterol at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at Week 12
percent changePlacebo Q2WPlacebo 420 mg SC QMEvolocumab 140 mg Q2WEvolocumab 420 mg QM
Percent Change From Baseline in Total Cholesterol at Week 122.69 ± 2.99-40.36 ± 2.571.17 ± 2.96-39.25 ± 2.40
Statistical analysis
  • Placebo Q2W vs Placebo 420 mg SC QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -43.05 · 95% CI -49.09 to -37.00Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Evolocumab 140 mg Q2W vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -40.42 · 95% CI -45.98 to -34.87Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 12

Percentage of participants who were below the target LDL-C of 70 mg/dL (1.8 mmol/L) based on the mean LDL-C data collected at weeks 10 and 12.

Time frame:
Weeks 10 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 12
percentage of participantsPlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L): Mean of Weeks 10 and 122.7 (0.5 to 13.8)89.9 (80.5 to 95.0)5.7 (1.6 to 18.6)97.2 (90.3 to 99.2)
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Cochran-Mantel-Haenszel · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 87.2 · 95% CI 72.6 to 92.8Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Cochran-Mantel-Haenszel · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 91.5 · 95% CI 76.9 to 96.1Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
percentage of participantsPlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percentage of Participants With Target LDL-C < 70 mg/dL (1.8 mmol/L) at Week 120.0 (0.0 to 10.2)90.6 (81.0 to 95.6)3.7 (0.7 to 18.3)89.4 (79.7 to 94.8)
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Cochran-Mantel-Haenszel · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 90.6 · 95% CI 76.6 to 95.6Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Cochran-Mantel-Haenszel · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 85.7 · 95% CI 68.2 to 91.9Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercentage of Participants With LDL-C Response: Mean of Weeks 10 and 12

Percentage of participants who had LDL-C response (50% reduction of LDL-C from baseline) based on the mean LDL-C using the data collected at weeks 10 and 12.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With LDL-C Response: Mean of Weeks 10 and 12
percentage of participantsPlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percentage of Participants With LDL-C Response: Mean of Weeks 10 and 120.0 (0.0 to 9.4)87.0 (77.0 to 93.0)5.7 (1.6 to 18.6)94.4 (86.4 to 97.8)
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Cochran-Mantel-Haenszel · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 87.0 · 95% CI 73.3 to 93.0Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Cochran-Mantel-Haenszel · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 88.7 · 95% CI 73.5 to 94.0Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 12

LDL-C Response is defined as a 50% reduction of LDL-C from Baseline.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 12
percentage of participantsPlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percentage of Participants With LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 120.0 (0.0 to 10.2)82.8 (71.8 to 90.1)3.7 (0.7 to 18.3)86.4 (76.1 to 92.7)
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Cochran-Mantel-Haenszel · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 82.8 · 95% CI 67.8 to 90.1Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Cochran-Mantel-Haenszel · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 82.7 · 95% CI 64.8 to 89.7Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Lipoprotein(a) [Lp(a)]: Mean of Weeks 10 and 124.96 ± 4.97-43.49 ± 4.4611.27 ± 4.37-29.16 ± 3.58
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -48.45 · 95% CI -57.78 to -39.11Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -40.43 · 95% CI -48.62 to -32.24Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Lp(a) at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lp(a) at Week 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Lp(a) at Week 121.87 ± 5.21-42.83 ± 4.6014.53 ± 5.64-23.73 ± 4.18
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -44.70 · 95% CI -54.76 to -34.65Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -38.26 · 95% CI -49.94 to -26.59Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Triglycerides: Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides: Mean of Weeks 10 and 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Triglycerides: Mean of Weeks 10 and 125.23 ± 4.77-9.86 ± 4.193.03 ± 4.85-16.64 ± 4.09
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = 0.008 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -15.09 · 95% CI -24.44 to -5.75Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -19.67 · 95% CI -28.30 to -11.05Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Triglycerides at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at Week 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Triglycerides at Week 1210.01 ± 5.63-7.55 ± 4.730.69 ± 5.56-11.66 ± 4.37
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = 0.008 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -17.56 · 95% CI -29.42 to -5.69Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -12.35 · 95% CI -23.04 to -1.67Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C): Mean of Weeks 10 and 121.01 ± 2.659.45 ± 2.351.86 ± 2.608.66 ± 2.18
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = 0.008 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 8.44 · 95% CI 3.35 to 13.52Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = 0.017 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 6.80 · 95% CI 2.10 to 11.50Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in HDL-C at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in HDL-C at Week 121.95 ± 2.889.89 ± 2.490.95 ± 2.977.12 ± 2.33
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = 0.008 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 7.94 · 95% CI 2.18 to 13.71Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = 0.017 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 6.17 · 95% CI 0.42 to 11.92Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline, Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C): Mean of Weeks 10 and 127.08 ± 5.32-15.88 ± 4.734.95 ± 4.97-22.87 ± 4.21
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = 0.0002 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -22.96 · 95% CI -33.12 to -12.81Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -27.81 · 95% CI -36.60 to -19.02Treatment difference = Evolocumab QM - Placebo QM
SecondaryPercent Change From Baseline in VLDL-C at Week 12

Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in VLDL-C at Week 12
percent changePlacebo Q2WEvolocumab 140 mg Q2WPlacebo QMEvolocumab 420 mg QM
Percent Change From Baseline in VLDL-C at Week 1211.23 ± 6.12-10.55 ± 5.221.72 ± 5.57-14.02 ± 4.42
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Repeated measures linear effects model · p = 0.0002 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -21.78 · 95% CI -34.31 to -9.25Treatment difference = Evolocumab Q2W - Placebo Q2W
  • Placebo QM vs Evolocumab 420 mg QM · Repeated measures linear effects model · p = < 0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: -15.74 · 95% CI -26.31 to -5.18Treatment difference = Evolocumab QM - Placebo QM

Adverse events

Collected over Mortality: from randomization to end of study (EOS) date; median (min, max) duration was 3.22 (0.99, 4.01) months. AEs: from first dose up to last dose + 30 days or EOS date, whichever was earlier; median (min, max) duration was 2.86 (1.02, 3.88) months.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W0/42 (0%)2/41 (4.9%)22/41 (53.7%)
Placebo QM0/41 (0%)4/41 (9.8%)22/41 (53.7%)
Evolocumab 140 mg Q2W0/79 (0%)6/79 (7.6%)45/79 (57%)
Evolocumab 420 mg QM0/80 (0%)1/80 (1.3%)42/80 (52.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlacebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QM
Angina pectorisCardiac disorders0/411/410/790/80
GoitreEndocrine disorders0/411/410/790/80
PeriarthritisMusculoskeletal and connective tissue disorders1/410/410/790/80
Cerebrovascular accidentNervous system disorders0/411/410/790/80
Diabetic nephropathyRenal and urinary disorders0/411/410/790/80
HypertensionVascular disorders1/410/410/790/80
Acute myocardial infarctionCardiac disorders0/410/411/790/80
Cardiac arrestCardiac disorders0/410/411/790/80
Cardiogenic shockCardiac disorders0/410/411/790/80
Upper gastrointestinal haemorrhageGastrointestinal disorders0/410/411/790/80
Most frequent other events
Showing 10 of 151
Most frequent other events
EventPlacebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QM
Upper respiratory tract infectionInfections and infestations5/412/417/796/80
HypertensionVascular disorders1/413/416/794/80
PyrexiaGeneral disorders0/413/412/790/80
Protein urine presentInvestigations0/410/414/790/80
Sinus bradycardiaCardiac disorders2/410/411/790/80
HyperbilirubinaemiaHepatobiliary disorders2/412/413/791/80
Urinary tract infectionInfections and infestations2/410/410/792/80
Back painMusculoskeletal and connective tissue disorders0/412/410/791/80
Blood pressure increasedInvestigations0/410/413/790/80
Urinary occult blood positiveInvestigations0/410/413/790/80

Baseline characteristics

Full Analysis Set: All participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QMTotal
Mean57.8 ± 9.859.4 ± 10.961.2 ± 10.660.9 ± 9.860.2 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QMTotal
Female1110282978
Male30315151163
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QMTotal
Hispanic or Latino00000
Not Hispanic or Latino41417980241
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QMTotal
Asian41417980241
Stratification Factor: Cardiovascular (CV) Risk
Stratification Factor: Cardiovascular (CV) Risk(Participants)Placebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QMTotal
High/Very High CV Risk37387374222
Not High/Very High CV Risk436619
Low-Density Lipoprotein Cholesterol (LDL-C)
Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL)Placebo Q2WPlacebo QMEvolocumab 140 mg Q2WEvolocumab 420 mg QMTotal
Mean120.9 ± 42.2117.1 ± 28.2113.7 ± 37.7115.5 ± 30.1116.1 ± 34.6
08

Study locations

31 sites
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Beijing Hospital
    Beijing, Beijing 100730, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • Sun Yat-sen Memorial Hospital Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • Guangzhou First Peoples  Hospital
    Guangzhou, Guangdong 510180, China
  • Guangzhou Red Cross Hospital
    Guangzhou, Guangdong 510220, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • The Second Nanning Peoples Hospital
    Nanning, Guangxi 530031, China
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Wuhan Puai Hospital
    Wuhan, Hubei 430030, China
  • Changsha Central Hospital
    Changsha, Hunan 410004, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • Inner Mongolia Peoples Hospital
    Huhehaote, Inner Mongolia 010017, China
  • Suzhou Kowloon Hospital
    Suzhou, Jiangsu 215000, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221006, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • The Second Affiliated Hospital to Nanchang University
    Nanchang, Jiangxi 330006, China
  • China-Japan Union Hospital of Jilin University
    Changchun, Jilin 130033, China
  • The Peoples Hospital of Liaoning Province
    Shenyang, Liaoning 110016, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shanghai Yangpu District Central Hospital
    Shanghai, Shanghai 200090, China
  • The First Affiliated Hospital of Xi An Jiao Tong University
    XI An, Shanxi 710061, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Tianjin Fourth Centre Hospital
    Tianjin, Tianjin 300140, China
  • Zhejiang Hospital
    Hangzhou, Zhejiang 310013, China
  • Taizhou Hospital of Zhejiang Province
    Linhai, Zhejiang 317000, China
  • Ningbo First Hospital
    Ningbo, Zhejiang 315010, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, 200040, China
09

References and documents

Publications

  • Tan H, Li W, Huang Z, Han Y, Huang X, Li D, Xing X, Monsalvo ML, Wu Y, Mao J, Xin L, Chen J; HUA TUO study investigators. Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO Randomized Clinical Trial. Cardiol Ther. 2023 Jun;12(2):341-359. doi: 10.1007/s40119-023-00304-x. Epub 2023 Feb 21. PubMed 36802321 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Apr 2020, 11 months.

Results were first posted in Aug 2021, 1 year 3 months after primary completion. A results delay was requested in Mar 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2018
First posted
Feb 15, 2018
StartActual
May 9, 2019
Primary completionActual
Apr 24, 2020
CompletionActual
May 9, 2020
Results delay requested
Mar 1, 2021
Results first posted
Aug 20, 2021
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03433755
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 15, 2018
Start date
May 9, 2019
Primary completion
Apr 24, 2020
Completion
May 9, 2020
Results posted
Aug 20, 2021
Last update
Mar 27, 2023

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion